• Cancel
    Date：2026-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=921

    Recently, CAStar Foods, a leader in China’s biosynthetic human-derived bioactive protein industry, announced the closing of a Series A+ financing round worth several hundred million RMB. The company’s independently developed A60 bioactive peptide replicates rare core protein fragments found in breast milk, boasting immense potential in the fields of nutritional immunology and health. Proceeds from this financing round will be mainly allocated to advancing the industrialization of the company’s core functional protein/peptide products and their global market expansion. CEC Capital acted as the exclusive financial advisor to CAStar Foods for this transaction.

  • Cancel
    Date：2026-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=919

    Recently, MicroCyto announced the closing of a new round of equity financing worth nearly 300 million RMB. The investors include Beijing New Materials Industry Investment Fund, Beijing Medical and Health Industry Investment Fund, Zhongguancun Capital, and

  • Cancel
    Date：2025-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=917

    Refine Biology recently announced the closing of a several hundred million RMB Series C financing round. The round was led by Xingxiang Asset Management Group, with participation from Royal Power XMXYG Fund as a co-investor. Proceeds from this financing w

  • Cancel
    Date：2025-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=908

    iRegene, a biotech company committed to becoming a global leader in universal chemically induced cell therapies, recently announced the successful completion of its Series B+ financing round. The round was jointly led by Northern Light Venture Capital, Ch

  • Cancel
    Date：2025-04

    Exclusive Financial Advisor to IREGENE

  • Cancel
    Date：2025-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=873

    Recently, Geneus Technologies, a leading domestic company in nanopore sequencing technology, announced the completion of a nearly RMB 100 million B++ round of financing. This round of funding was led by CDBT Group, with participation from Si Chuan Venture

  • Cancel
    Date：2025-02

    Exclusive Financial Advisor to QL Biopharm

  • Cancel
    Date：2024-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=854

    Recently, Dingzhi Dental, a leading brand and expert in complex dental implants in China, announced the closing of its Series A financing, raising several hundred million RMB, with Eight Roads as the sole investor. CEC Capital served as the exclusive

  • Cancel
    Date：2024-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=842

    MicroCyto announced that it has raised over 300 million yuan in Series A financing. The round was led by Beijing Jingguorui Investment, with participation from Beijing Medical and Health Industry Investment Fund, Shenzhen Capital Group, and Hebei Producti